Illumina (NASDAQ:ILMN) Reaches New 12-Month High - Here's What Happened

Key Points

• Illumina shares reached a new 52-week high, trading as high as $236 and last changing hands around $229.47, up from the prior close of $222.29.
• The company exceeded quarterly expectations, reporting $1.31 in EPS versus the $1.23 consensus and revenue of $1.16 billion, up 9.4% year over year. Illumina maintained fiscal 2026 guidance of $5.30–$5.40 in EPS.
• Analyst sentiment remains mixed, with a consensus “Hold” rating and average price target of $199.12, while insiders have sold more than 2 million shares worth approximately $436.6 million over the past 90 days.

Illumina, Inc. (NASDAQ:ILMN - Get Free Report)'s stock price reached a new 52-week high during trading on Wednesday . The stock traded as high as $236.00 and last traded at $229.4720, with a volume of 361659 shares changing hands. The stock had previously closed at $222.29.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Barclays lifted their price target on Illumina from $145.00 to $160.00 and gave the stock an "underweight" rating in a report on Friday, July 31st. Evercore reaffirmed an "outperform" rating on shares of Illumina in a research note on Monday, July 6th. Royal Bank Of Canada boosted their target price on shares of Illumina from $170.00 to $230.00 and gave the company an "outperform" rating in a report on Friday, July 31st. Sanford C. Bernstein reissued a "market perform" rating and issued a $215.00 price target on shares of Illumina in a research note on Friday, July 31st. Finally, Guggenheim raised their price target on shares of Illumina from $200.00 to $226.00 and gave the stock a "buy" rating in a report on Friday, July 31st. Ten investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Illumina currently has an average rating of "Hold" and a consensus target price of $199.12.

Illumina Stock Performance

The firm has a market capitalization of $34.13 billion, a price-to-earnings ratio of 42.25, a PEG ratio of 2.95 and a beta of 1.46. The firm has a 50 day moving average price of $201.78 and a 200-day moving average price of $163.78. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.23 by $0.08. The firm had revenue of $1.16 billion for the quarter, compared to analysts' expectations of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The firm's revenue was up 9.4% compared to the same quarter last year. During the same quarter last year, the company earned $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, sell-side analysts expect that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Insider Activity at Illumina

In other Illumina news, Director Keith Meister sold 457,858 shares of Illumina stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $200.10, for a total value of $91,617,385.80. Following the transaction, the director directly owned 2,372,694 shares in the company, valued at approximately $474,776,069.40. The trade was a 16.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last 90 days, insiders have sold 2,062,465 shares of company stock valued at $436,589,802. Insiders own 2.90% of the company's stock.

Institutional Trading of Illumina

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Elevation Wealth Partners LLC grew its holdings in Illumina by 52.5% during the 2nd quarter. Elevation Wealth Partners LLC now owns 244 shares of the life sciences company's stock valued at $43,000 after buying an additional 84 shares in the last quarter. Meeder Advisory Services Inc. lifted its position in Illumina by 3.1% during the first quarter. Meeder Advisory Services Inc. now owns 2,822 shares of the life sciences company's stock valued at $348,000 after purchasing an additional 85 shares during the last quarter. Gabelli Funds LLC grew its stake in shares of Illumina by 2.0% in the 1st quarter. Gabelli Funds LLC now owns 5,000 shares of the life sciences company's stock worth $616,000 after buying an additional 100 shares in the last quarter. MCF Advisors LLC boosted its stake in Illumina by 172.4% during the second quarter. MCF Advisors LLC now owns 158 shares of the life sciences company's stock worth $28,000 after buying an additional 100 shares during the period. Finally, WealthCollab LLC raised its position in Illumina by 51.5% in the 1st quarter. WealthCollab LLC now owns 303 shares of the life sciences company's stock worth $37,000 after purchasing an additional 103 shares during the period. Hedge funds and other institutional investors own 89.42% of the company's stock.

Illumina Company Profile

Illumina, Inc develops and manufactures genomic analysis technologies used by researchers, healthcare providers, pharmaceutical companies and other organizations. Its offerings include next-generation DNA sequencing systems, microarray platforms, consumables, laboratory services and bioinformatics software designed to help analyze genetic variation and biological functions.

The company's sequencing instruments include systems for a range of applications and throughput levels, such as the NovaSeq, NextSeq, MiSeq and iSeq platforms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.